Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Mirati Therapeutics (MRTX) Prices 4.33M Share Common Offering at $202/Sh
October 28, 2020 5:57 AM EDTMirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before... More
Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
October 26, 2020 6:31 AM EDTOppenheimer analyst Jay Olson raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $225.00 (from $190.00) while maintaining an Outperform rating.
The analyst commented, "The triple meeting featured MRTX's adagrasib (formerly MRTX849) data in NSCLC and CRC from the KRYSTAL-1 clinical trial. In NSCLC,... More
